A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

In this phase 2 trial involving adults with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis.

​   The New England Journal of Medicine: Search Results in Endocrinology